Luminal tumours, accounting for about 50% of MIBCs, present high expression of urothelial differentiation markers (GATA3, FOXA1, KRT20, uroplakins) and are enriched in activating mutations of FGFR3 [3]. The gene discussed is FOXA1; the disease is neoplasm.